Skip to content

HerResolve™ in Detecting the Presence of Endometriosis Among Symptomatic Women

Clinical Study for HerResolve™ in Detecting the Presence of Endometriosis Among Symptomatic Women of Ages 18-49 Years Considering Laparoscopy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07006987
Enrollment
100
Registered
2025-06-05
Start date
2025-10-14
Completion date
2037-06-01
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Brief summary

Endometriosis (EMS) is a common gynecological disease that affects 176 million girls and women globally. EMS affects 5-10% of women and adolescents within the reproductive age range of 15-49 years, and for those facing infertility, this figure may climb up to 50%. EMS can start at the first menstrual period and last until menopause. Shockingly, between 50% and 80% of women grappling with pelvic pain are found to have EMS. The formation of scar tissue (adhesions, fibrosis) within the pelvis and other parts of the body can cause severe pain and lead to infertility.

Interventions

DEVICEA non-invasive blood-based (HerResolve)

A non-invasive blood-based test can detect endometriosis as compared to diagnostic laparoscopy

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

To demonstrate the performance of the non-invasive blood-based test in detecting endometriosis as compared to diagnostic laparoscopy

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Females aged 18 to 49 with mild to severe symptoms of pelvic pain and/or abnormal bleeding. * Diagnostic laparoscopy is scheduled with histology on any visually suspected endometriosis, and all reports (surgical and pathology) to confirm a positive result. If no visually suspicious endometriotic lesions are seen, biopsies from random areas during the laparoscopy procedure to confirm a negative histopathology result. * Blood drawn during secretory or proliferative phase of the menstrual cycle * Provide written informed consent to participate in the study and provide medical history on medications.

Exclusion criteria

* Patients who object to medical history collection and data requests * Patients with cancer and/or undergoing chemotherapy and/or radiotherapy * Patients who are unable or do not undergo laparoscopic surgery * Patients participating in additional interventional clinical studies * Pregnant, lactating, or subjects who are not healthy enough for blood donation. * Blood drawn during menses or ovulation phase of menstrual cycle * Females who are post-menopausa

Design outcomes

Primary

MeasureTime frameDescription
Detecting endometriosis as compared to diagnostic laparoscopy1 weekTo demonstrate the performance of the non-invasive blood-based test in detecting endometriosis as compared to diagnostic laparoscopy

Secondary

MeasureTime frameDescription
Performance Objective:1 yearSensitivity: 90% (95% CI: 85%, 98%) Specificity: 90% (95% CI: 85%, 94%) Statistical Analysis will also include PPV and NPV. Sub-group analysis will be performed

Countries

China

Contacts

Primary ContactElaine Ng
elaineng@cuhk.edu.hk35052745

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026